The French trial called STIM (Stop Imatinib) - Chronic Myeloid Leukemia
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features
August 2, 2011, Haematologica
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
July 6, 2011, Oncology Practice
Multicenter Trial Estimating the Persistence of Molecular
Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (STIM 2)
April 2011, ClinicalTrials.gov
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 3, 2011, Cancer Journal for Clinicians
August 2, 2011, Haematologica
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
July 6, 2011, Oncology Practice
Multicenter Trial Estimating the Persistence of Molecular
Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (STIM 2)
April 2011, ClinicalTrials.gov
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 3, 2011, Cancer Journal for Clinicians
CML Patients Stay in Remission Two Years After Imatinib
October 21, 2010, DoctorsLounge
Some with leukemia can safely stop Gleevec
October 2010, Caring4cancer
Could Some Patients Stop Taking Their CML Pills? VIDEO
October 2010, Patient Power
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
October 2010,The Lancet Oncology, Early Online Publication
Some With Once-Deadly Leukemia Can Take a Break From Gleevec
Small minority of CML patients went off the drug for 2 years with no sign of recurrence
October 2010, Healthday, U.S. News
STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML
January 2010, MedConnect
STIM Study Shows CML Complete Molecular Remission
Possible to Maintain Following Imatinib Discontinuation
December 19, 2008, CMLSupport
The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early
December 6, 2008, CMLinfo
October 21, 2010, DoctorsLounge
Some with leukemia can safely stop Gleevec
October 2010, Caring4cancer
Could Some Patients Stop Taking Their CML Pills? VIDEO
October 2010, Patient Power
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
October 2010,The Lancet Oncology, Early Online Publication
Some With Once-Deadly Leukemia Can Take a Break From Gleevec
Small minority of CML patients went off the drug for 2 years with no sign of recurrence
October 2010, Healthday, U.S. News
STIM Study Examines Sustainability of Complete Molecular Response After Stopping Imatinib in CML
January 2010, MedConnect
STIM Study Shows CML Complete Molecular Remission
Possible to Maintain Following Imatinib Discontinuation
December 19, 2008, CMLSupport
The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early
December 6, 2008, CMLinfo
